Synapse - AACR project GENIE: 100,000 cases and beyond

AACR project GENIE: 100,000 cases and beyond Journal Article

Authors:	Pugh, T. J.; Bell, J. L.; Bruce, J. P.; Doherty, G. J.; Galvin, M.; Green, M. F.; Hunter-Zinck, H.; Kumari, P.; Lenoue-Newton, M. L.; Li, M. M.; Lindsay, J.; Mazor, T.; Ovalle, A.; Sammut, S. J.; Schultz, N.; Yu, T. V.; Sweeney, S. M.; Bernard, B.; for the AACR Project GENIE Consortium, Genomics and Analysis Working Group
Contributors:	Arcila, M. E.; Benayed, R.; Berger, M. F.; Bhuiya, M.; Brannon, A. R.; Brown, S.; Chakravarty, D.; Chu, C.; de Bruijn, I.; Galle, J.; Gao, J.; Gardos, S.; Gross, B.; Kundra, R.; Kung, A. L.; Ladanyi, M.; Lavery, J. A.; Li, X.; Lisman, A.; Mastrogiacomo, B.; McCarthy, C.; Nichols, C.; Ochoa, A.; Panageas, K. S.; Philip, J.; Pillai, S.; Riely, G. J.; Rizvi, H.; Rudolph, J.; Sawyers, C. L.; Schrag, D.; Schwartz, J.; Sheridan, R.; Solit, D.; Wang, A.; Wilson, M.; Zehir, A.; Zhang, H.; Zhao, G.
Article Title:	AACR project GENIE: 100,000 cases and beyond
Abstract:	The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international pan-cancer registry with the goal to inform cancer research and clinical care worldwide. Founded in late 2015, the mile-stone GENIE 9.1-public release contains data from >110,000 tumors from >100,000 people treated at 19 cancer centers from the United States, Canada, the United Kingdom, France, the Netherlands, and Spain. Here, we demonstrate the use of these real-world data, harmonized through a centralized data resource, to accurately predict enrollment on genome-guided trials, discover driver alterations in rare tumors, and identify cancer types without actionable mutations that could benefit from comprehensive genomic analysis. The extensible data infrastructure and governance framework support additional deep patient phenotyping through biopharmaceutical collaborations and expansion to include new data types such as cell-free DNA sequencing. AACR Project GENIE continues to serve a global precision medicine knowledge base of increasing impact to inform clinical decision-making and bring together cancer researchers internationally. SIGNIFICANCE: AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged as a powerful resource to evaluate genome-guided clinical trial design, uncover drivers of cancer subtypes, and inform real-world use of genomic data. ©2022 The Authors; Published by the American Association for Cancer Research.
Keywords:	adult; controlled study; gene mutation; major clinical study; somatic mutation; genetics; mutation; sunitinib; united states; genetic analysis; neoplasm; neoplasms; tumor associated leukocyte; quality control; phenotype; gastrointestinal stromal tumor; imatinib; cohort analysis; pathology; mutational analysis; cetuximab; cancer research; panitumumab; tumor suppressor gene; ubiquitination; mismatch repair; clinical evaluation; gene fusion; scoring system; genomics; clinical decision making; pluripotent stem cell; transcriptome; personalized medicine; non small cell lung cancer; dna methyltransferase 3a; trametinib; high throughput sequencing; humans; human; male; female; article; precision medicine; alpelisib; whole exome sequencing; cell-free nucleic acids; cell free nucleic acid; circulating free dna; aacr project
Journal Title:	Cancer Discovery
Volume:	12
Issue:	9
ISSN:	2159-8274
Publisher:	American Association for Cancer Research
Date Published:	2022-09-01
Start Page:	2044
End Page:	2057
Language:	English
DOI:	10.1158/2159-8290.Cd-21-1547
PUBMED:	35819403
PROVIDER:	scopus
PMCID:	PMC9437568
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137136780&doi=10.1158%2f2159-8290.CD-21-1547&partnerID=40&md5=27591e736efec76644ae9a1deff9e356
Notes:	Article -- Export Date: 3 October 2022 -- Source: Scopus